AMENDMENTS TO THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the application.

LISTING OF CLAIMS

Claims 1-18 (cancelled).

19. (new) A compound of the formula (I)



I

or a pharmaceutically acceptable salt of the compound, prodrug of the compound or ester of the compound, wherein:

G is selected from the group consisting of

a) 

b)  c) 

d)  e)  f)  and g)  ;

where Q is selected from the group consisting of NH and O, Q' is selected from the group consisting of H, C_1-C_6 alkyl, phenyl and phenyl-C_1-C_4-alkyl, and R' is selected from the group consisting of H and C_1-C_4 alkyl;

B is $(CH_2)_m(CH=CH)_pY$, wherein m = 1,2,3, p = 0 and Y is CH_2;

X is selected from the group consisting of CH_2 and C=O;

R1 is selected from the group consisting of H, C_1-C_4 alkyl, C_1-C_4 alkoxy, OH, halogen, and CF_3;

A is selected from the group consisting of CH_2, NH, O, and $S(O)_n$ wherein n is zero, 1 or 2;

R2 is selected from the group consisting of phenyl, naphthyl, pyridine, pyrazine, pyridazine, pyrimidine, thiophene, pyrrole, pyrazole, imidazole, oxazole and isoxazole, unsubstituted or optionally substituted with one to three substituents independently selected from the group consisting of H, C_1-C_4 alkyl, C_1-C_4 alkoxy, OH, halogen, and CF_3; and

R is selected from the group consisting of hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_4 alkynyl, aryl and aryl-C_1-C_4 alkyl.

20. (new) A compound according to claim 19, wherein

G is selected from the group consisting of


and

; and

R2 is selected from the group consisting of phenyl, thiophene, oxazole, isoxazole, and pyridine, unsubstituted or optionally substituted with one to three substituents independently selected from the group consisting of H, C_1-C_4 alkyl, C_1-C_4 alkoxy, OH, halogen and CF_3.

21. (new) A pharmaceutical composition comprising a therapeutically effective amount of a compound or a pharmaceutically acceptable salt of the compound, prodrug of the compound or ester of the compound having the formula (I):



I

wherein:

G is selected from the group consisting of

a) 

b) 

c) 

d) 

e) 

f) 

and g) 

;

where Q is selected from the group consisting of NH and O, Q' is selected from the group consisting of H, C_1-C_6 alkyl, phenyl, and phenyl-C_1-C_4-alkyl, and R' is selected from the group consisting of H and C_1-C_4 alkyl;

B is $(CH_2)_m(CH=CH)_pY$, wherein m = 1,2,3, p = 0 and Y is CH_2;

X is selected from the group consisting of CH_2 and C=O;

R1 is selected from the group consisting of H, C_1-C_4 alkyl, C_1-C_4 alkoxy, OH, halogen, and CF_3;

A is selected from the group consisting of CH_2, NH, O, and $S(O)_n$ wherein n is zero, 1 or 2;

R2 is selected from the group consisting of phenyl, naphthyl, pyridine, pyrazine, pyridazine, pyrimidine, thiophene, pyrrole, pyrazole, imidazole, oxazole and isoxazole, unsubstituted or optionally substituted with one to three substituents independently selected from the group consisting of H, C_1-C_4 alkyl, C_1-C_4 alkoxy, OH, halogen, and CF_3; and

R is selected from the group consisting of hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_4 alkynyl, aryl and aryl-C_1-C_4 alkyl.

22. (new) A pharmaceutical composition of claim 21 wherein:

G is selected from the group consisting of

 and  ; and

R2 is selected from the group consisting of phenyl, thiophene, oxazole, isoxazole, and pyridine, unsubstituted or optionally substituted with one to three substituents independently selected from the group consisting of H, C_1-C_4 alkyl, C_1-C_4 alkoxy, OH, halogen and CF_3.

23. (new) A method for treating a condition mediated by the $\alpha_v\beta_3$ integrin in a mammal in need of such treatment, including a human, comprising administering to said mammal an effective $\alpha_v\beta_3$ inhibiting amount of a compound of formula (I)



I

or a pharmaceutically acceptable salt of the compound, prodrug of the compound or ester of the compound, wherein:

G is selected from the group consisting of

a) 

b)  c) 

d)  e)  f)  and g)  ;

where Q is selected from the group consisting of NH and O, Q' is selected from the group consisting of H, C_1-C_6 alkyl, phenyl, and phenyl-C_1-C_4-alkyl, and R' is

selected from the group consisting of H and C_1-C_4 alkyl;
B is $(CH_2)_m(CH=CH)_pY$, wherein m = 1,2,3, p = 0 and Y is CH_2;
X is selected from the group consisting of CH_2 and C=O;
R1 is selected from the group consisting of H, C_1-C_4 alkyl, C_1-C_4 alkoxy, OH, halogen, and CF_3;
A is selected from the group consisting of CH_2, NH, O, and $S(O)_n$ wherein n is zero, 1 or 2;
R2 is selected from the group consisting of phenyl, naphthyl, pyridine, pyrazine, pyridazine, pyrimidine, thiophene, pyrrole, pyrazole, imidazole, oxazole and isoxazole unsubstituted or optionally substituted with one to three substituents independently selected from the group consisting of H, C_1-C_4 alkyl, C_1-C_4 alkoxy, OH, halogen, and CF_3; and
R is selected from the group consisting of hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_4 alkynyl, aryl and aryl-C_1-C_4 alkyl.

24. (new) The method of claim 23 wherein:
G is selected from the group consisting of


and

; and

R2 is selected from the group consisting of phenyl, thiophene, oxazole, isoxazole, and pyridine unsubstituted or optionally substituted with one to three substituents independently selected from the group consisting of H, C_1-C_4 alkyl, C_1-C_4 alkoxy, OH, halogen and CF_3.

25. (new) The method according to claim 23, wherein the condition treated is selected from the group consisting of bone resorption, osteoporosis, humoral hypercalcemia of malignancy, Paget's disease, tumor metastasis, neoplasia, angiogenesis, diabetic retinopathy, arthritis, psoriasis, periodontal disease and smooth muscle cell migration.

26. (new) The method according to claim 23, wherein the condition treated is selected from the group consisting of solid tumor growth, tumor angiogenesis and restenosis.

27. (new) A combined method of treatment of cancer or of controlling the growth of a neoplasm in a mammal suffering from cancer, including a human, the method comprising administering simultaneous, separately or sequentially,

a compound of formula (I)



I

or a pharmaceutically acceptable salt of the compound, a prodrug of the compound or an ester of the compound, wherein:

G is selected from the group consisting of

a) 

b)  c) 

d)  e)  f)  and g)  ;

where Q is selected from the group consisting of NH and O, Q' is selected from the group consisting of H, C_1-C_6 alkyl, phenyl, and phenyl-C_1-C_4-alkyl, and R' is selected from the group consisting of H and C_1-C_4 alkyl;

B is $(CH_2)_m(CH=CH)_pY$, wherein m = 1,2,3, p = 0 and Y is CH_2;

X is selected from the group consisting of CH_2 and C=O;

R1 is selected from the group consisting of H, C_1-C_4 alkyl, C_1-C_4 alkoxy, OH,

halogen, and CF_3;

A is selected from the group consisting of CH_2, NH, O, and $S(O)_n$ wherein n is zero, 1 or 2;

R2 is selected from the group consisting of phenyl, naphthyl, pyridine, pyrazine, pyridazine, pyrimidine, thiophene, pyrrole, pyrazole, imidazole, oxazole and isoxazole unsubstituted or optionally substituted with one to three substituents independently selected from the group consisting of H, C_1-C_4 alkyl, C_1-C_4 alkoxy, OH, halogen, and CF_3; and

R is selected from the group consisting of hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_4 alkynyl, aryl and aryl-C_1-C_4-alkyl; and

an additional antitumor agent; in amounts and close enough together in time sufficient to produce a therapeutically useful effect.

28. (new) The method according to claim 27, wherein the additional antitumor agent is selected from the group consisting of an antineoplastic topoisomerase II inhibitor, an antineoplastic antimicrotubule agent, an antineoplastic alkylating agent, an antineoplastic antimetabolite and an antineoplastic topoisomerase I inhibitor.

29. (new) A product containing a compound of formula (I) a compound of formula (I)



I

or a pharmaceutically acceptable salt of the compound, a prodrug of the compound or an ester of the compound, wherein:

G is selected from the group consisting of

a) 

b) 

c) 

d) 

e) 

f) 

and g) 

;

where Q is selected from the group consisting of NH and O, Q' is selected from the group consisting of H, C_1-C_6 alkyl, phenyl, and phenyl-C_1-C_4-alkyl, and R' is selected from the group consisting of H and C_1-C_4 alkyl;

B is $(CH_2)_m(CH=CH)_pY$, wherein m = 1,2,3, p = 0 and Y is CH_2;

X is selected from the group consisting of CH_2 and C=O;

R1 is selected from the group consisting of H, C_1-C_4 alkyl, C_1-C_4 alkoxy, OH, halogen, and CF_3;

A is selected from the group consisting of CH_2, NH, O, and $S(O)_n$ wherein n is zero, 1 or 2;

R2 is selected from the group consisting of phenyl, naphthyl, pyridine, pyrazine, pyridazine, pyrimidine, thiophene, pyrrole, pyrazole, imidazole, oxazole and isoxazole unsubstituted or optionally substituted with one to three substituents independently selected from the group consisting of H, C_1-C_4 alkyl, C_1-C_4 alkoxy, OH, halogen, and CF_3; and

R is selected from the group consisting of hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_4 alkynyl, aryl and aryl-C_1-C_4 alkyl; and

an effective antineoplastic amount of an additional antitumor agent as a combined preparation for simultaneous, separate or sequential use in anti-cancer therapy.

30. (new) The product according to claim 29, wherein the additional antitumor agent is selected from an antineoplastic topoisomerase II inhibitor, an antineoplastic antimicrotubule agent, an antineoplastic alkylating agent, an

antineoplastic antimetabolite and an antineoplastic topoisomerase I inhibitor.

31. (new) A combined method of treatment of cancer or of controlling the growth of a neoplasm in a mammal suffering from cancer, including a human, said method comprising administering simultaneous, separately or sequentially, a compound selected from the group consisting of:

3-phenyl-N-{4-[2-(2-pyridinylamino)ethyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-beta-alanine,

3-phenyl-N-{4-[3-(2-pyridinylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-beta-alanine,

3-phenyl-N-{4-[4-(2-pyridinylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-beta-alanine,

N-{4-[2-(1H-imidazol-2-ylamino)ethyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenyl-beta-alanine,

N-{4-[3-(1H-imidazol-2-ylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenyl-beta-alanine,

N-{4-[2-(1H-imidazol-2-ylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenyl-beta-alanine,

3-(3-pyridinyl)-N-{4-[2-(2-pyridinylamino)ethyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-beta-alanine,

3-(3-pyridinyl)-N-{4-[3-(2-pyridinylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-beta-alanine,

3-(3-pyridinyl)-N-{4-[4-(2-pyridinylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-beta-alanine,

N-{4-[2-(1H-imidazol-2-ylamino)ethyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)-beta-alanine,

N-{4-[3-(1H-imidazol-2-ylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)-beta-alanine,

N-{4-[4-(1H-imidazol-2-ylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)-beta-alanine,

N-{3-oxo-4-[2-(2-pyridinylamino)ethyl]-3,4-dihydro-2H-1,4-benzoxazin-7-

yl}-3-phenyl-beta-alanine,

N-{3-oxo-4-[3-(2-pyridinylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenyl-beta-alanine,

N-{3-oxo-4-[4-(2-pyridinylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenyl-beta-alanine,

N-{4-[2-(1H-imidazol-2-ylamino)ethyl]-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenyl-beta-alanine,

N-{4-[3-(1H-imidazol-2-ylamino)propyl]-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenyl-beta-alanine,

N-{4-[4-(1H-imidazol-2-ylamino)butyl]-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenyl-beta-alanine,

N-{3-oxo-4-[2-(2-pyridinylamino)ethyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)-beta-alanine,

N-{3-oxo-4-[3-(2-pyridinylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)-beta-alanine,

N-{3-oxo-4-[4-(2-pyridinylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)-beta-alanine,

N-{4-[2-(1H-imidazol-2-ylamino)ethyl]-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)-beta-alanine,

N-{4-[3-(1H-imidazol-2-ylamino)propyl]-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)-beta-alanine,

N-{4-[4-(1H-imidazol-2-ylamino)butyl]-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)-beta-alanine,

3-({3-oxo-4-[3-(1H-imidazol-2-ylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}oxy)-3-phenylpropanoic acid,

3-({3-oxo-4-[4-(2-pyridinylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}oxy)-3-phenylpropanoic acid,

3-({3-oxo-4-[4-(1H-imidazol-2-ylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}oxy)-3-phenylpropanoic acid,

3-({3-oxo-4-[3-(2-pyridinylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}oxy)-3-(3-pyridinyl)propanoic acid,

3-({3-oxo-4-[4-(2-pyridinylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}oxy)-3-(3-pyridinyl)propanoic acid,

3-({3-oxo-4-[3-(1H-imidazol-2-ylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}oxy)-3-(3-pyridinyl)propanoic acid,

3-({3-oxo-4-[4-(1H-imidazol-2-ylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}oxy)-3-(pyridinyl)propanoic acid,

3-({3-oxo-4-[4-(2-pyridinylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}sulfanyl)-3-phenylpropanoic acid,

3-({3-oxo-4-[3-(1H-imidazol-2-ylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}sulfanyl)-3-phenylpropanoic acid,

3-({3-oxo-4-[4-(1H-imidazol-2-ylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}sulfanyl)-3-phenylpropanoic acid,

3-({3-oxo-4-[3-(2-pyridinylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}sulfanyl)-3-(3-ppyridinyl)propanoic acid,

3-({3-oxo-4-[4-(2-pyridinylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}sulfanyl)-3-(3-pyridinyl)propanoic acid,

3-({3-oxo-4-[3-(1H-imidazol-2-ylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}sulfanyl)-3-(3-pyridinyl)propanoic acid,

3-({3-oxo-4-[4-(1H-imidazol-2-ylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}sulfanyl)-3-(3-pyridinyl)propanoic acid,

4-{3-oxo-4-[4-(pyridin-2-ylamino)-butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenylbutanoic acid,

4-{3-oxo-4-[3-(1H-imidazol-2-ylamino)-propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenylbutanoic acid,

4-{3-oxo-4-[4-(1H-imidazol-2-ylamino)-butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenylbutanoic acid,

4-{3-oxo-4-[4-(pyridin-2-ylamino)-butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)butanoic acid,

4-{3-oxo-4-[3-(1H-imidazol-2-ylamino)-propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)butanoic acid, and

4-{3-oxo-4-[4-(1H-imidazol-2-ylamino)-butyl]-3,4-dihydro-2H-1,4-

benzoxazin-7-yl}-3-(3-pyridinyl)butanoic acid or a pharmaceutically acceptable salt of said compound; and

an additional antitumor agent; in amounts and close enough together in time sufficient to produce a therapeutically useful effect.

32 (new) The method according to claim 31 wherein the additional antitumor agent is selected from the group consisting of an antineoplastic topoisomerase II inhibitor, an antineoplastic antimicrotubule agent, an antineoplastic alkylating agent, an antineoplastic antimetabolite and an antineoplastic topoisomerase I inhibitor.

33. (new) A product containing a compound selected from the group consisting of:

3-phenyl-N-{4-[2-(2-pyridinylamino)ethyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-beta-alanine,

3-phenyl-N-{4-[3-(2-pyridinylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-beta-alanine,

3-phenyl-N-{4-[4-(2-pyridinylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-beta-alanine,

N-{4-[2-(1H-imidazol-2-ylamino)ethyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenyl-beta-alanine,

N-{4-[3-(1H-imidazol-2-ylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenyl-beta-alanine,

N-{4-[2-(1H-imidazol-2-ylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenyl-beta-alanine,

3-(3-pyridinyl)-N-{4-[2-(2-pyridinylamino)ethyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-beta-alanine,

3-(3-pyridinyl)-N-{4-[3-(2-pyridinylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-beta-alanine,

3-(3-pyridinyl)-N-{4-[4-(2-pyridinylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-beta-alanine,

N-{4-[2-(1H-imidazol-2-ylamino)ethyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)-beta-alanine,

N-{4-[3-(1H-imidazol-2-ylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)-beta-alanine,

N-{4-[4-(1H-imidazol-2-ylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)-beta-alanine,

N-{3-oxo-4-[2-(2-pyridinylamino)ethyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenyl-beta-alanine,

N-{3-oxo-4-[3-(2-pyridinylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenyl-beta-alanine,

N-{3-oxo-4-[4-(2-pyridinylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenyl-beta-alanine,

N-{4-[2-(1H-imidazol-2-ylamino)ethyl]-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenyl-beta-alanine,

N-{4-[3-(1H-imidazol-2-ylamino)propyl]-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenyl-beta-alanine,

N-{4-[4-(1H-imidazol-2-ylamino)butyl]-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenyl-beta-alanine,

N-{3-oxo-4-[2-(2-pyridinylamino)ethyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)-beta-alanine,

N-{3-oxo-4-[3-(2-pyridinylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)-beta-alanine,

N-{3-oxo-4-[4-(2-pyridinylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)-beta-alanine,

N-{4-[2-(1H-imidazol-2-ylamino)ethyl]-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)-beta-alanine,

N-{4-[3-(1H-imidazol-2-ylamino)propyl]-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)-beta-alanine,

N-{4-[4-(1H-imidazol-2-ylamino)butyl]-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)-beta-alanine,

3-({3-oxo-4-[3-(1H-imidazol-2-ylamino)propyl]-3,4-dihydro-2H-1,4-

benzoxazin-7-yl}oxy)-3-phenylpropanoic acid,

3-({3-oxo-4-[4-(2-pyridinylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}oxy)-3-phenylpropanoic acid,

3-({3-oxo-4-[4-(1H-imidazol-2-ylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}oxy)-3-phenylpropanoic acid,

3-({3-oxo-4-[3-(2-pyridinylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}oxy)-3-(3-pyridinyl)propanoic acid,

3-({3-oxo-4-[4-(2-pyridinylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}oxy)-3-(3-pyridinyl)propanoic acid,

3-({3-oxo-4-[3-(1H-imidazol-2-ylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}oxy)-3-(3-pyridinyl)propanoic acid,

3-({3-oxo-4-[4-(1H-imidazol-2-ylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}oxy)-3-(pyridinyl)propanoic acid,

3-({3-oxo-4-[4-(2-pyridinylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}sulfanyl)-3-phenylpropanoic acid,

3-({3-oxo-4-[3-(1H-imidazol-2-ylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}sulfanyl)-3-phenylpropanoic acid,

3-({3-oxo-4-[4-(1H-imidazol-2-ylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}sulfanyl)-3-phenylpropanoic acid,

3-({3-oxo-4-[3-(2-pyridinylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}sulfanyl)-3-(3-ppyridinyl)propanoic acid,

3-({3-oxo-4-[4-(2-pyridinylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}sulfanyl)-3-(3-pyridinyl)propanoic acid,

3-({3-oxo-4-[3-(1H-imidazol-2-ylamino)propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}sulfanyl)-3-(3-pyridinyl)propanoic acid,

3-({3-oxo-4-[4-(1H-imidazol-2-ylamino)butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}sulfanyl)-3-(3-pyridinyl)propanoic acid,

4-{3-oxo-4-[4-(pyridin-2-ylamino)-butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenylbutanoic acid,

4-{3-oxo-4-[3-(1H-imidazol-2-ylamino)-propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenylbutanoic acid,

4-{3-oxo-4-[4-(1H-imidazol-2-ylamino)-butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-phenylbutanoic acid,

4-{3-oxo-4-[4-(pyridin-2-ylamino)-butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)butanoic acid,

4-{3-oxo-4-[3-(1H-imidazol-2-ylamino)-propyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)butanoic acid, and

4-{3-oxo-4-[4-(1H-imidazol-2-ylamino)-butyl]-3,4-dihydro-2H-1,4-benzoxazin-7-yl}-3-(3-pyridinyl)butanoic acid or a pharmaceutically acceptable salt of said compound; and

an effective antineoplastic amount of an additional antitumor agent as a combined preparation for simultaneous, separate or sequential use in anti-cancer therapy.

34. (new) The product according to claim 33, wherein the additional antitumor agent is selected from an antineoplastic topoisomerase II inhibitor, an antineoplastic antimicrotubule agent, an antineoplastic alkylating agent, an antineoplastic antimetabolite and an antineoplastic topoisomerase I inhibitor.